AB
The startup develops gene therapies that utilize adeno-associated viral vectors to deliver corrective genetic material for rare and debilitating diseases. Their technology aims to provide long-term or permanent therapeutic benefits, enhancing patient care and clinical outcomes.
Updated 3 months ago
Funding
$240K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops gene therapies that utilize adeno-associated viral vectors to deliver corrective genetic material for rare and debilitating diseases. Their technology aims to provide long-term or permanent therapeutic benefits, enhancing patient care and clinical outcomes.